Drugs - Xagena.net - Update in Medicine

Search results for "Nexavar"

Keytruda for hepatocellular carcinoma, approved by FDA

The FDA ( Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for patients with hepatocellular carcinoma ( HCC ) who have been previously treated with Sorafen ... read article

Nexavar to treat metastatic differentiated thyroid cancer, FDA approved

The FDA ( Food and Drug Administration ) has expanded the approved uses of Nexavar ( Sorafenib ) to treat metastatic differentiated thyroid cancer. Sorafenib works by inhibiting multiple proteins i ... read article

Sorafenib has shown success in advanced differentiated thyroid cancer patients

The cancer drug Sorafenib ( Nexavar ) holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial. If approved for use in thyr ... read article

RAI-refractory differentiated thyroid cancer: Sorafenib shows significant improvement in progression-free survival

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced positive data from the phase III DECISION trial investigating the use of Sorafenib ( Nexavar ) tablets in patients with locally ... read article

2013 - DECISION Trial: Sorafenib improves progression-free survival in patients with radioactive iodine refractory differentiated thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals have announced that a phase III trial of Nexavar ( Sorafenib ) tablets in patients with locally advanced or metastatic radioactive iodine ( RAI )-refractory d ... read article

Everolimus, new indication: treatment of patients with subependymal giant cell astrocytoma associated with tuberous sclerosis

The FDA ( Food and Drug Administration ) approved Afinitor ( Everolimus ) to treat patients with subependymal giant cell astrocytoma ( SEGA ) associated with tuberous sclerosis, a rare genetic disorde ... read article

Metastatic renal-cell carcinoma: switch to metronomic chemotherapy could offer new treatment option

A new multi-targeted chemo-switch drug regimen shows promising anti-tumour activity with manageable side effects in patients with metastatic renal-cell carcinoma ( RCC ), a disease with few treatment ... read article

Advanced kidney cancer: Sorafenib shrinks tumor prior to surgery

Physicians who conducted a pilot study at University of North Carolina ( UNC ) Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug Sorafenib ( Nexavar ) can reduce t ... read article

Advances in renal cell carcinoma management

Renal cell carcinoma ( RCC ) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy. In contrast ... read article

Sorafenib improves progression free survival in patients with breast cancer

In the advanced breast cancer, one study has found that if Sorafenib ( Nexavar ) is combined with the chemotherapy drug, Capecitabine ( Xeloda ), it makes a significant difference to the time women l ... read article

Sorafenib targets acute myeloid leukemia driven by mutant FLT3 gene

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia ( AML ), the most common and lethal form of adult leukemia, Researc ... read article

Sorafenib: older renal cancer patients appear to benefit from treatment

Older and younger patients with renal cancer derive similar benefit from Sorafenib ( Nexavar ) therapy and tolerate the drug equally well. Although the risk of being diagnosed with cancer increase ... read article

BRAF mutations in colorectal cancer cause resistance to anti-EGFR therapy

European Researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with Cetuximab ( Erbitux ) and Panitumumab ( Vectibix ). ... read article

Everolimus prolongs progression-free survival in patients with metastatic kidney cancer who have failed on other treatments

Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failure ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article